Mounjaro savings card — manufacturer program changes 2026

Pharmacist here. The reason is FDA indication and NDC codes. Even though tirzepatide is the same compound: - Mounjaro (NDC 00002-1504-xx) — FDA approved for type 2 diabetes, billed under diabetes drug class - Zepbound (NDC 00002-2355-xx) — FDA approved for chronic weight management, billed under anti-obesity drug class Insurers set coverage by drug class. Most plans cover diabetes medications broadly but explicitly exclude anti-obesity medications. It's the same molecule but legally, regulatorily, and from a billing perspective, they are different products. It's frustrating but that's how the system works.

So what happens if your doctor prescribes Mounjaro off-label for obesity? If your A1C is normal, can they still prescribe the diabetes version and your insurance just covers it?

Technically a doctor can prescribe any FDA-approved drug off-label. BUT the pharmacy will submit it with a diagnosis code. If the diagnosis code is obesity (E66.01) and the drug is Mounjaro, many pharmacy systems will flag it. The insurer may reject it if the diagnosis doesn't match the approved indication. If the doctor uses a diabetes diagnosis code (like E11.9 for T2D) when the patient doesn't actually have diabetes, that's insurance fraud. Full stop. I've seen doctors lose their licenses over this. Don't go down that road.

But what about the gray area? My A1C is 5.8 — that's officially prediabetes (5.7-6.4 range). My doctor prescribed Mounjaro with a prediabetes diagnosis (R73.03) and my insurance (Aetna) covered it. Prediabetes is a metabolically legitimate reason to prescribe a diabetes medication. It's not fraud if the diagnosis is real. Now, did I also happen to lose 45 lbs? Yes. But the clinical rationale for the prescription was prediabetes management and diabetes prevention. My A1C is now 5.1.